EVALUATING THE EFFICACY OF TREATMENT BASED ON ANNEXIN A1 (ANXA1) LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK INHIBITORS

Authors

  • Norbo‘toyev Olimjon Mustafaqul o‘g‘li Tashkent State Medical University, Department of Internal Diseases No. 2 in Family Medicine, Tashkent, Uzbekistan. Author
  • Abdurakhmonova Nargiza Mirza-Bakhtiyorkhanovna Tashkent State Medical University, Department of Internal Diseases No. 2 in Family Medicine, Tashkent, Uzbekistan. Author

Keywords:

Rheumatoid arthritis (RA), Annexin A1 (ANXA1), treatment efficacy, DAS28, disease-modifying antirheumatic drugs (DMARDs), Janus kinase (JAK) inhibitors.

Abstract

 Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, for which early diagnosis, accurate assessment of disease activity, and prediction of treatment efficacy are among the urgent tasks of modern rheumatology. In recent years, Annexin A1 (ANXA1), an endogenous anti-inflammatory protein, has garnered significant interest as an important biomarker of the immune-inflammatory process. Specifically, evaluating changes in ANXA1 levels in patients with rheumatoid arthritis treated with JAK inhibitors allows for the early detection of treatment response, monitoring of disease activity, and prediction of therapeutic efficacy. Studying the correlation between ANXA1 levels and clinical and laboratory activity indices is crucial for selecting individualized treatment strategies, assessing the likelihood of achieving remission, and preventing disease exacerbation in patients receiving JAK inhibitors.

References

1.Akhmedov, Kh.S., Gadaev, A.G., & Khurramov, M.O. (2015). Immune changes in patients with rheumatoid arthritis according to the regions of Uzbekistan. *Uzbekiston tibbiyot jurnali* [Medical Journal of Uzbekistan], (1), 17-21.

2.Akhmedov, Kh.S., Gadaev, A.G., & Abzalova, D.A. (2015). Variation in clinical indicators of rheumatoid arthritis depending on the climatic-geographical and ecological regions of Uzbekistan. *O'zbekiston terapiya axborotnomasi* [Therapy Bulletin of Uzbekistan], (4), 97-100.

3.Akhmedov, Kh.S. (2016). Osobennosti sostoyaniya immunnogo statusa pri revmatoidnom artrite v zavisimosti ot klimato-geograficheskikh i ekologicheskikh zon Uzbekistana [Features of the immune status in rheumatoid arthritis depending on the climatic-geographical and ecological zones of Uzbekistan]. *Nauchno-prakticheskaya revmatologiya* [Scientific and Practical Rheumatology], *54* (2), 183-186.

4.Peng, J., Zhang, X., Chen, L., et al. (2026). Development and validation of a combined ultrasound-immunological model for rheumatoid arthritis activity assessment. *Frontiers in Immunology*, *17*, 1669766. doi: 10.3389/fimmu.2026.1669766. PMID: 41401292.

5.Park, J.K., Lee, Y.J., Shin, K., et al. (2026). Current and future treatment of rheumatoid arthritis. *Korean Journal of Internal Medicine*, *41* (1), 1-15. doi: 10.3904/kjim.2025.401. PMID: 41409811.

6.Li, C., Wang, H., Chen, Y., et al. (2026). Catalpol mitigates rheumatoid arthritis by targeting neutrophil extracellular trap-associated inflammatory responses. *Frontiers in Pharmacology*, *17*, 1628734. doi: 10.3389/fphar.2026.1628734. PMID: 41284570.

7.Schett, G., & Gravallese, E. (2022). Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. *Nature Reviews Rheumatology*, *18* (11), 631-645. doi: 10.1038/s41584-022-00845-w. PMID: 36137645.

8.Kleyer, A., Simon, D., Stemmler, F., et al. (2021). Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. *Annals of the Rheumatic Diseases*, *80* (6), 765-772. doi: 10.1136/annrheumdis-2020-218732. 2021;

9.Alivernini, S., Tolusso, B., Petricca, L., et al. Synovial tissue biomarkers in rheumatoid arthritis: current evidence and future perspectives.

Humby, F., Durez, P., Buch, M.H., et al. (2023). Precision medicine through synovial tissue pathology in rheumatoid arthritis. *Nature Reviews Rheumatology*, *19* (2), 111-126.

10.Kerschbaumer, A., Sepriano, A., Smolen, J.S., et al. (2023). Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature review informing the 2022 EULAR recommendations. *Annals of the Rheumatic Diseases*.

Bozec, A., & Zaiss, M.M. (2021). T cells in bone remodeling and inflammatory bone loss. *Current Opinion in Rheumatology*, *33* (4), 327-333.

11.Nygaard, G., & Firestein, G.S. (2020). Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. *Nature Reviews Rheumatology*, *16* (6), 316-333. doi: 10.1038/s41584-020-0413-5.

Downloads

Published

2026-10-17